EMPOWERPHARM Trademark

Trademark Overview


On Tuesday, October 26, 2021, a trademark application was filed for EMPOWERPHARM with the United States Patent and Trademark Office. The USPTO has given the EMPOWERPHARM trademark a serial number of 97092446. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Tuesday, May 2, 2023. This trademark is owned by EmpowerPharm Inc.. The EMPOWERPHARM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of various diseases, conditions and disorders; Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of anxiety, stress, pain and insomnia; Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of anxiety; Natural health products, namely, glucosamine, turmeric supplements, dietary supplements to aid digestion, melatonin, sleep support supplements, fish oils, probiotics in tablet, capsule, gummy vitamin and liquid form; vitamin supplements; mineral supplements; vitamin and mineral food supplements; vitamin and mineral dietary supplements; vitamin preparations; mineral preparations; multivitamins; prenatal vitamins; calcium supplements; nutritional supplements for general health and well-being, namely, magnesium in tablets, capsules, gummies, and liquids; dietary supplements for promoting weight loss; over the counter medications for treating ...
empowerpharm

General Information


Serial Number97092446
Word MarkEMPOWERPHARM
Filing DateTuesday, October 26, 2021
Status638 - NEW APPLICATION - ASSIGNED TO EXAMINER
Status DateTuesday, May 2, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of various diseases, conditions and disorders; Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of anxiety, stress, pain and insomnia; Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of anxiety; Natural health products, namely, glucosamine, turmeric supplements, dietary supplements to aid digestion, melatonin, sleep support supplements, fish oils, probiotics in tablet, capsule, gummy vitamin and liquid form; vitamin supplements; mineral supplements; vitamin and mineral food supplements; vitamin and mineral dietary supplements; vitamin preparations; mineral preparations; multivitamins; prenatal vitamins; calcium supplements; nutritional supplements for general health and well-being, namely, magnesium in tablets, capsules, gummies, and liquids; dietary supplements for promoting weight loss; over the counter medications for treating aches, pains, headaches, arthritis pain, sprains, and for treatment of minor joint injuries and muscle soreness, nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, naproxen sodium, acetaminophen, cold, sore throat and cough medications, guaifenesin, liquid cough medicines with dextromethorphan, decongestant nasal sprays, pseudoephedrine, phenylephrine, allergy medications, antihistamine pills and liquids, diphenhydramine, chlorpheniramine, brompheniramine, loratadine, fexofenadine, cetirizine, stomach upset medications, namely, probiotic preparations for medical purposes to help maintain a natural balance of flora in the digestive system, antidiarrhea medicines, loperamide, bismuth, nausea treatment preparations, pharmaceutical preparations for the treatment of vomiting and motion sickness, dimenhydrinate; cannabidiol (CBD) oil for medical purposes; cannabidiol (CBD) for medical purposes; cannabidiol (CBD) for medical purposes in the form of suppositories, sublingual doses that dissolve in the mouth, creams, ointments, and doses for absorption in the mucous membranes; tablets, capsules, gummies, suppositories, skin patches, sublingual doses, extended release tablets and liquids for therapeutic purposes containing cannabidiol (CBD); herbal supplements containing cannabidiol (CBD); Liquid nutritional supplement containing cannabidiol (CBD) for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia; tetrahydrocannabinol (THC) for medical purposes; tetrahydrocannabinol (THC) for medical purposes in sublingual doses and doses for absorption in the mucous membranes; tablets, capsules, gummies, suppositories, skin patches, sublingual doses, extended release tablets and liquid for therapeutic purposes containing tetrahydrocannabinol (THC) and containing a combination of tetrahydrocannabinol (THC) together with cannabidiol (CBD)

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 9, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEmpowerPharm Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBurlington, Ontario L7L6M1
CA

Trademark Events


Event DateEvent Description
Tuesday, May 2, 2023ASSIGNED TO EXAMINER
Tuesday, December 20, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, December 20, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 20, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, November 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 29, 2021NEW APPLICATION ENTERED